Contact
searchSearch
HMP Global
Login

Multiple Myeloma Resource Center

News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
From Oncology
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
News
Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma
01/31/2024
Emry Lloyd
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib,...
01/31/2024
Journal of Clinical Pathways
News
Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens
01/18/2024
Grace Taylor, MS, MA
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD,...
01/18/2024
Journal of Clinical Pathways
News
Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT
11/29/2023
Amber Denham
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of...
11/29/2023
Oncology
From Oncology
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guidelines for Multiple Myeloma
01/11/2023
Yvette C. Terrie, BS Pharm, RPh
The NCCN recently published updated recommendations for the management of MM regarding newly diagnosed transplant-eligible and transplant-ineligible patients with MM, maintenance, and previously treated MM, and principles of management of...
The NCCN recently published updated recommendations for the management of MM regarding newly diagnosed transplant-eligible and transplant-ineligible patients with MM, maintenance, and previously treated MM, and principles of management of...
The NCCN recently published...
01/11/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways

Expert Insights

Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways
Thomas Martin, MD, UCSF
Interview
Isatuximab Plus Carfilzomib and Dexamethasone for Relapsed MM: Results From the IKEMA Trial
03/30/2022
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses...
03/30/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
Videos
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
03/05/2021
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO,...
03/05/2021
Journal of Clinical Pathways
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
12/20/2020
12/20/2020
Journal of Clinical Pathways
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
12/09/2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD,...
12/09/2020
Journal of Clinical Pathways
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
Videos
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
12/08/2020
12/08/2020
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Advancing Value-Based Oncology With the Predictable Cost of Care Working Group: Part 2
03/17/2025
Gordon Kuntz; Carole Tremonti, RN, MBA
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology...
03/17/2025
Journal of Clinical Pathways
Brian S.
Interview
Key Advancements in Immunotherapy for Endometrial Cancer
03/13/2025
Brian M. Slomovitz, MD, MS
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses...
03/13/2025
Journal of Clinical Pathways
Brufsky Headshot
Interview
Transforming Metastatic Breast Cancer Care With AI and Real-World Evidence
03/11/2025
Adam Brufsky, MD, PhD
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky,...
03/11/2025
Journal of Clinical Pathways

Newsfeed

News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
News
Progression-Free Survival Benefits of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone For Multiple Myeloma
01/31/2024
Emry Lloyd
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib, lenalidomide, and dexamethasone have shown significant results in progression-free survival rates for patients with newly diagnosed multiple myeloma.
Daratumumab, bortezomib,...
01/31/2024
Journal of Clinical Pathways
News
Efficacy in Clinical Trials vs Effectiveness in the Real World for Multiple Myeloma Treatment Regimens
01/18/2024
Grace Taylor, MS, MA
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.
A study by Kelvin Chan, MD, PhD,...
01/18/2024
Journal of Clinical Pathways
News
Clonal Hematopoiesis Associated With High Risk of CVD Among Patients With MM Undergoing HCT
11/29/2023
Amber Denham
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of indeterminate potential was both significantly and independently associated with risk of cardiovascular disease among patients with multiple myeloma undergoing hematopoietic cell transplant, according to a...
Clonal hematopoiesis of...
11/29/2023
Oncology
Conference Coverage
BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma
12/12/2022
Craig Ostroff
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Isatuximab + Carfilzomib and Dexamethasone in Early vs Late Relapsed Multiple Myeloma
12/12/2022
Katie Herman
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
High-Risk Lesions: A Consistent Predictor of Ultra-High Risk Multiple Myeloma
12/11/2022
Katie Herman
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP,...
12/11/2022
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Safety and Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
04/06/2022
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world...
04/06/2022
Journal of Clinical Pathways
Quiz
Quiz: Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM
12/01/2021
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation...
12/01/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Belantamab Mafodotin for Relapsed/Refractory MM
10/14/2021
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab...
10/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Daratumumab for MM
09/09/2021
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding...
09/09/2021
Journal of Clinical Pathways
Quiz
Quiz: Daratumumab Among Patients With MM
07/19/2021
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based...
07/19/2021
Journal of Clinical Pathways
Quiz
Quiz: DRd vs Rd for Newly Diagnosed MM
03/12/2021
03/12/2021
Journal of Clinical Pathways
Quiz
Quiz: Maintenance Therapy Use Following Transplantation for Newly-Diagnosed MM
12/17/2020
12/17/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Jolynn Tumolo
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Model Predicts Outcomes After BCMA CAR-T in Patients With RRMM
12/10/2024
Jolynn Tumolo
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model that uses disease-, treatment-, and inflammation-related variables to predict outcomes after anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T therapy (CAR-T) in patients with...
Researchers have created a model...
12/10/2024
Journal of Clinical Pathways
Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
News
Benefit of Adding Daratumumab to Bortezomib, Lenalidomide, and Dexamethasone Therapy for Transplant-Eligible Patients With Newly Diagnosed MM
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use